Anavex Life Sciences "announced positive topline results from its Phase 2b/3 ANAVEX(R)2-73-AD-004 clinical trial of oral ANAVEX2-73, or blarcamesine, for the treatment of mild cognitive impairment due to Alzheimer’s disease, AD, and mild AD . ANAVEX(R)2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results. Next step, in light of this data, is meeting with regulatory authorities to discuss this data in the context of ongoing development with an aim to bring this therapy to patients in Europe, Asia-Pacific, and the U.S."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVXL:
- Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022
- Anavex Shoots Up After Positive Topline Data
- ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease
- Anavex Stock: Volatility Beckons but the Pipeline Has Big Potential, Says Analyst
- Anavex Shares (NASDAQ: AVXL) Plunge after Q4 Earnings Miss
